Doxil Injection, Suspension, Liposomal
Product Images NDC 0338-0063

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Doxil (NDC 0338-0063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

Chemical structure of doxorubicin hydrochloride, the active ingredient in DOXIL. The diagram depicts the molecular arrangement including functional groups and hydrochloride salt notation.*

FDA Label Image

Mpeg-dspe Structural Formula (Image 02)

Chemical structure diagram depicting a component of the DOXIL (doxorubicin hydrochloride) liposomal formulation. The diagram shows a molecular structure including sodium salt, ester, amide, and long-chain hydrocarbon groups, with notation indicating a polymeric segment with approximately 45 repeating units.*

FDA Label Image

Hspc Structural Formula (Image 03)

Chemical structure diagram depicting the molecular arrangement of the active ingredient in DOXIL, doxorubicin hydrochloride. The structure shows a phospholipid component with variable chain lengths specified as m, n = 14 or 16, corresponding to liposomal formulation components.*

FDA Label Image

Representation Of A Stealth Liposome (Image 04)

An illustration diagram showing the liposomal structure of the DOXIL injection suspension. The diagram labels three parts: the MPEG-DSPE coating on the outer layer, the aqueous core containing entrapped doxorubicin hydrochloride, and the liposomal bilayer surrounding the core.*

FDA Label Image

Figure 1 (Image 05)

A survival curve graph showing the percent of subjects progression-free over time in months. Two treatment groups are compared: DOXIL plus Bortezomib and Bortezomib alone. The graph includes a table listing the number of subjects at risk in each group at various time points. Statistical data such as p-value, hazard ratio (HR), and confidence interval (CI) are also displayed.*

FDA Label Image

Representative 20 mg Container Label (Image 06)

DOXIL 2 mg/mL injection, suspension, liposomal, labeled as doxorubicin hydrochloride liposome injection. The vial contains 20 mg in 10 mL and is a single-dose vial for intravenous infusion only. Labeler is Baxter Healthcare Company. Storage instructions state to refrigerate at 2°-8°C and not to freeze. The label includes warnings not to substitute for doxorubicin hydrochloride and notes the product is cytotoxic.*

FDA Label Image

Representative Carton Label 0338-0063-01 (Image 07)

DOXIL 2 mg/mL liposomal injection vial label showing doxorubicin hydrochloride as the active ingredient. The label indicates a 20 mg dose in a 10 mL single-dose vial supplied by Baxter Healthcare Company. It includes storage instructions, dilution guidance, and a warning that it is for intravenous infusion after dilution only.*

FDA Label Image

Representative Carton Label 20 mg Taiwan (Image 08)

DOXIL (doxorubicin hydrochloride liposome injection) 2 mg/mL intravitreal injection carton label. The label displays the proprietary name DOXIL prominently with the generic name doxorubicin hydrochloride, describing it as a liposome injection. It includes warnings about the liposomal formulation and not substituting for doxorubicin hydrochloride. The label specifies the manufacturer as Baxter Healthcare Corporation, Deerfield, IL, and includes NDC 0338-0063-01. Detailed ingredient and formulation information is provided in small print on the side panel.*

FDA Label Image

Representative Container Label 50 mg (Image 09)

DOXIL 2 mg/mL liposomal injection carton label for doxorubicin hydrochloride by Baxter Healthcare Company. The label indicates a 20 mg in 10 mL (2 mg/mL) single-dose vial for intravenous infusion only, with storage instructions to refrigerate at 2°-8°C and avoid freezing. The package warns against substituting the liposomal formulation and includes proprietary and trademark notices, ingredients details, and barcode.*

FDA Label Image

Representative Carton Label 0338-0067-01 (Image 10)

DOXIL (doxorubicin hydrochloride liposome injection) 2 mg/mL injection suspension label showing a 50 mg dose in 25 mL single-dose vial. The label states it is a liposomal formulation for intravenous infusion only, with warnings not to substitute for doxorubicin hydrochloride. It includes storage instructions to refrigerate at 2°-8°C and discard unused portion. Manufactured by Baxter Healthcare Corporation.*

FDA Label Image

Representative Carton Label 50 mg Taiwan (Image 11)

DOXIL (doxorubicin hydrochloride liposome injection) carton label for 50 mg in 25 mL (2 mg/mL) single-dose vial. The label includes instructions for intravenous infusion after dilution, storage conditions (refrigerate 2°-8°C, do not freeze), and cautions that it is a liposomal formulation and cytotoxic. The labeler is Baxter Healthcare Company.*

FDA Label Image

Image 12

DOXIL (doxorubicin hydrochloride liposome injection) packaging label for 2 mg/mL intravitreal injection by Baxter Healthcare Company. The label includes drug name, NDC 0338-0067-01, formulation details noting a liposomal suspension, and manufacturer information. It also lists lipid components and excipients. The label warns not to substitute other doxorubicin hydrochloride formulations and shows regulatory and batch identification sections.*

FDA Label Image

Image 13

Packaging label for DOXIL (doxorubicin hydrochloride liposome injection) 2 mg/mL in a 25 mL single-dose vial. The label states it is a liposomal formulation for intravenous infusion only, manufactured by Baxter Healthcare Corporation. The packaging includes storage instructions, barcode, and warnings not to substitute for doxorubicin hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.